Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomarin Pharmaceuticals (BMRN)

Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know

BMRN : 60.16 (-1.60%)
A $4.8 Billion Reason to Buy BioMarin Stock Today

BioMarin stock soars as the biotech firm announces a $4.8 billion acquisition of Amicus Therapeutics. The transaction could push BMRN shares even higher in 2026.

FOLD : 14.25 (+0.28%)
BMRN : 60.16 (-1.60%)
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today

BMRN : 60.16 (-1.60%)
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook

BioMarin to Gain Galafold ® (migalastat) for Fabry Disease and Pombiliti ® (cipaglucosidase alfa-atga) + Opfolda ® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth...

FOLD : 14.25 (+0.28%)
BMRN : 60.16 (-1.60%)
1 Oversold Stock Primed to Rebound and 2 That Underwhelm

1 Oversold Stock Primed to Rebound and 2 That Underwhelm

SHW : 325.35 (+0.40%)
BMRN : 60.16 (-1.60%)
CHD : 85.46 (+0.25%)
2 Reasons to Like BMRN and 1 to Stay Skeptical

2 Reasons to Like BMRN and 1 to Stay Skeptical

BMRN : 60.16 (-1.60%)
Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks

Q3 Earnings Outperformers: BioMarin Pharmaceutical (NASDAQ:BMRN) And The Rest Of The Therapeutics Stocks

BMRN : 60.16 (-1.60%)
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know

ABT : 124.81 (+0.22%)
BMRN : 60.16 (-1.60%)
ABBV : 229.89 (+0.48%)
DXCM : 67.42 (+0.84%)
BIIB : 176.33 (+0.86%)
BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?

BioMarin Pharmaceutical (BMRN): Buy, Sell, or Hold Post Q3 Earnings?

BMRN : 60.16 (-1.60%)
1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

1 Safe-and-Steady Stock on Our Watchlist and 2 We Question

SBGI : 15.21 (-0.85%)
BMRN : 60.16 (-1.60%)
BGS : 4.54 (+2.25%)

Barchart Exclusives

Have a MERRY Christmas With These 9 Unusually Active Options
In the past year, there have been many interesting stocks and their unusually active options to discuss. Whether you do or don’t celebrate Christmas, here are nine stocks whose unusually active options make for good bets in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar